These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33567917)

  • 1. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
    Mehta CC; Bhatt HG
    Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
    Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
    Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
    Mariotti L; Pollock K; Guettler S
    Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
    Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
    Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.
    McGonigle S; Chen Z; Wu J; Chang P; Kolber-Simonds D; Ackermann K; Twine NC; Shie JL; Miu JT; Huang KC; Moniz GA; Nomoto K
    Oncotarget; 2015 Dec; 6(38):41307-23. PubMed ID: 26513298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
    Yakkala PA; Naaz F; Shafi S; Kamal A
    Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
    Ma L; Wang X; Jia T; Wei W; Chua MS; So S
    Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
    Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
    Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
    Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
    Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
    Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
    Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
    PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
    Lakshmi TV; Bale S; Khurana A; Godugu C
    Curr Drug Targets; 2017; 18(10):1214-1224. PubMed ID: 27425647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
    Jang MK; Mashima T; Seimiya H
    Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for tankyrases as antineoplastic targets in lung cancer.
    Busch AM; Johnson KC; Stan RV; Sanglikar A; Ahmed Y; Dmitrovsky E; Freemantle SJ
    BMC Cancer; 2013 Apr; 13():211. PubMed ID: 23621985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights of tankyrases: A novel target for drug discovery.
    Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
    Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
    Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
    Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor.
    Ryu H; Nam KY; Kim HJ; Song JY; Hwang SG; Kim JS; Kim J; Ahn J
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
    Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
    PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
    Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
    Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of a Screening Hit toward M2912, an Oral Tankyrase Inhibitor with Antitumor Activity in Colorectal Cancer Models.
    Buchstaller HP; Anlauf U; Dorsch D; Kögler S; Kuhn D; Lehmann M; Leuthner B; Lodholz S; Musil D; Radtki D; Rettig C; Ritzert C; Rohdich F; Schneider R; Wegener A; Weigt S; Wilkinson K; Esdar C
    J Med Chem; 2021 Jul; 64(14):10371-10392. PubMed ID: 34255518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.